Predicting Proangiogenic Potential of Extracellular Vesicles via miR-130a and TGFβ
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for improving vascular remodeling in patients with diabetes and obesity have failed to provide significant benefits, highlighting the need for novel treatment options that can enhance neovascularization of damaged tissues.
Innovation Solution
A method for predicting the proangiogenic activity of extracellular vesicle (EV) preparations by quantifying the miR-130a microRNA and transforming growth factor beta (TGFβ) content, allowing for the selection of effective EVs for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic approaches are used for improving vascular remodeling in patients with diabetes and obesity, then treatment is provided, but significant benefits are not achieved
Solution Approach 1:
The invention changes the therapeutic parameter from conventional treatments to specifically selected EV preparations characterized by high proangiogenic potential, identified through miR-130a and TGFβ content thresholds. This parameter change enables reliable therapeutic efficacy by selecting only those EV preparations that meet predetermined cargo composition criteria
Solution Approach 2:
The invention creates a predictive model that copies the functional outcome (proangiogenic activity) through measurable surrogate markers (miR-130a and TGFβ content). By measuring these cargo components and comparing against predetermined values, the system predicts therapeutic effectiveness without requiring complex functional assays
2Measurement precision
If EV preparations are selected without predictive criteria, then all EVs are available for use, but effective proangiogenic EVs cannot be distinguished from inactive ones
Solution Approach 1:
The invention extracts the key predictive elements (miR-130a and TGFβ) from the complex EV cargo composition. By focusing measurement on these specific components and comparing their content against predetermined threshold values, the method achieves precise prediction of proangiogenic activity while maintaining simple operational procedures
Solution Approach 2:
The invention establishes predetermined threshold values for miR-130a and TGFβ content that serve as critical parameters for distinguishing active from inactive EVs. By changing the selection criterion from general EV presence to specific cargo composition thresholds, accurate prediction is achieved through simple quantitative comparison
Data Source
Figure 1A
Figure 1B~1C
Figure 2A~2B
AI summary
The present invention relates to an in vitro method for predicting the proangiogenic activity of preparations of extracellular vesicles (EVs), preferably blood-derived EVs, wherein the method is based on the combined determination of the content of transforming growth factor beta (TGFβ) and microRNA-130a. Also disclosed is a method of manufacturing a preparation of extracellular vesicles (EVs) predicted to have strong proangiogenic activity and the EVs preparations thereof, which are effective for the therapeutic treatment of ischemic diseases, ischemic injuries and pathological conditions associated with risk of cardiovascular disease, or for use in wound healing.